Magnesium as Adjuvant for Sciatic Block (Mg)

Campus Bio-Medico University of Rome

Status: Completed

Conditions: Hallux Valgus

Treatments: Drug: Ropivacaine; Drug: Magnesium Sulfate

Study type: Interventional

Funder types: Other

Identifiers

NCT02198547

CarGalMg

Details and patient eligibility

About

The aim of the study is to evaluate if Magnesium added to ropivacaine can reduce onset time and can enhance offset time.

Full description

Patients are randomly divided into two groups: group "M" (Ropivacaina 7,5 mg/ml with Mg 4 mg/Kg)and group"C" (without Mg).

Standard monitoring is applied to each patient in perioperative period. An indipendent observer collect data: time to perform block, sensitivity onset,motor onset, pain during surgery and complication.

In the post-operative period till 24 hours for each patient is evaluated off-set time, pain and analgesic consumption.

Enrollment: 60 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• given consent
• allux valgus correction surgery

Exclusion criteria

• allergy to local anesthetic
• infection in the site of puncture

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

60 participants in 2 patient groups

Ropivacaine Magnesium sulfate

Experimental group

Description:

Locoregional anesthesia for valgus allux correction with ropivacaine 7,5 mg/ml and Mg 4 mg/Kg. Sciatic block at popliteal level.

Treatment:

Drug: Magnesium Sulfate

Ropivacaine

Active Comparator group

Description:

Patients undergoing allux valgus correction with locoregional anesthesia with ropivacaine 7,5 mg/ml, without MG

Treatment:

Drug: Ropivacaine